EpiTET Therapeutics
Biotechnology company developing first-in-class, oral small-molecule molecular glue degraders that selectively target and eliminate pathogenic macrophages for the treatment of chronic inflammatory diseases. Research focus includes target discovery, preclinical studies and peer-reviewed publications in areas such as endometriosis, metabolic liver disease (MASH) and cancer.
Industries
N/A
Nr. of Employees
small (1-50)
Services
Research and preclinical development of selective macrophage-targeted small-molecule therapeutics.
Research and preclinical development of selective macrophage-targeted small-molecule therapeutics.
Expertise Areas
- Molecular glue degrader development
- Macrophage-targeted therapeutics
- Inflammation and immunology
- Target discovery and validation
Key Technologies
- Molecular glue degrader platforms
- Small-molecule oral therapeutics
- Macrophage-targeting strategies
- Target discovery and validation methods
News & Updates
Peer-reviewed article linking TET3 in macrophages to endometriosis.
Peer-reviewed article proposing TET3 targeting in macrophages as a treatment strategy for endometriosis.
Research linking TET3 activity to insulin resistance mechanisms.
Study describing a role for let-7 in metformin's effect on hepatic glucose production.
Research on hepatic TET3 contribution to type 2 diabetes via HNF4α isoform regulation.
Study showing let-7 role in suppressing liver fibrosis.
Peer-reviewed article linking TET3 in macrophages to endometriosis.
Peer-reviewed article proposing TET3 targeting in macrophages as a treatment strategy for endometriosis.
Research linking TET3 activity to insulin resistance mechanisms.
Study describing a role for let-7 in metformin's effect on hepatic glucose production.
Research on hepatic TET3 contribution to type 2 diabetes via HNF4α isoform regulation.
Study showing let-7 role in suppressing liver fibrosis.